On the auspicious occasion of the New Year, the Thalassemia & Sickle Cell Society (TSCS) extends its warmest wishes for a ...

Curating a diet plan from a professional is definitely an interesting, and sometimes exciting, process. But did you know that ...

As 2026 approaches, doctors urge prioritising preventive health tests to catch illnesses early. Key screenings like CBC, ...

FDA approves Agios' Aqvesme for anemia in alpha and beta thalassemia, backed by Phase 3 data and a REMS safety program.

A population-based “Screen and Treat for Anaemia Reduction” (STAR) strategy can significantly reduce anaemia, especially ...

Approval was based on the phase 3 ENERGIZE and ENERGIZE-T studies evaluating the safety and efficacy of mitapivat in adults with alpha- or beta-thalassemia.

Planning to get married? This country has made premarital medical examinations mandatory for couples from this year, linking ...

AQVESME is the only FDA-approved medicine for anemia in both non-transfusion-dependent and transfusion-dependent alpha- or ...

The Cash Price Laboratory service is set to launch on Jan. 14. UNC Health Southeastern Main Laboratory hours are Monday ...

Nagpur: With the district sickle cell patient load rising to around 2,900, Indira Gandhi Govt Medical College and Hospital's Daga Hospital has made sc.

The US FDA has approved mitapivat, the first oral medicine for treating anemia caused by thalassemia. At present, mitapivat ...

In a statement, Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) said that the FDA officially approved Aqvesme to treat anemia in ...